TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16832124

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (antibiotics) administered on the day before and the day of embryo transfer
Number of subjects: 350

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 350
Study: 12510037

Group type: EXPERIMENTAL
Intervention: Pulmonary-artery catheter
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Standard care without pulmonary-artery catheter
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1994
Study: 10750134

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No ICD (Control)
Number of subjects: 204
Study: 8900553

Group type: EXPERIMENTAL
Intervention: Methotrexate (50 mg per m2) + Misoprostol (800 micrograms)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Misoprostol (vaginal administration)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Overall procedure satisfaction
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring
Number of subjects: 282
Study: 1797509

Group type: EXPERIMENTAL
Intervention: Insulin and Glyburide (IG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin and Placebo (IP)
Number of subjects: 20
Study: 7005630

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30741856

Group type: EXPERIMENTAL
Intervention: Personal supervision (SUP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nonpersonal supervision (NPS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Unsupervised control (CON)
Number of subjects: 85
Study: 31679347

Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28142085

Group type: EXPERIMENTAL
Intervention: Crisis response plan
Number of subjects: 97

Group type: COMPARATOR
Intervention: Contract for safety
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Crisis response planning
Number of subjects: 97
Study: 25841177

Group type: EXPERIMENTAL
Intervention: Cognitive control training (CCT), consisting of 10 online training sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition, consisting of 10 online training sessions.
Number of subjects: 0
Study: 24106896

Group type: EXPERIMENTAL
Intervention: Palonosetron plus dexamethasone
Number of subjects: 1411

Group type: COMPARATOR
Intervention: Ondansetron/granisetron plus dexamethasone
Number of subjects: 1411
Study: 21390173

Group type: EXPERIMENTAL
Intervention: Adenosine (80 µg/kg/min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Remifentanil (saline control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sevoflurane (saline control)
Number of subjects: 90
Study: 19433134

Group type: EXPERIMENTAL
Intervention: Active treatment (combined mechanical vibrations, continuous passive motion, and thermotherapy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 71
Study: 17970683

Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 0.5W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 1.0W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 0.5W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 1.0W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 1.5W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 2.0W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 1.5W power output
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 2.0W power output
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 65
Study: 15471073

Group type: EXPERIMENTAL
Intervention: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Number of subjects: 59

Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg daily by oral administration
Number of subjects: 59
Study: 11327741

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCTs) infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs) in a 1:1 mixture with LCTs
Number of subjects: 9
Study: 9649466

Group type: EXPERIMENTAL
Intervention: Propranolol plus prazosin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propranolol plus ISMN
Number of subjects: 56
Study: 8189403

Group type: EXPERIMENTAL
Intervention: Stress condition (mental arithmetic)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No stress condition (30-min initial baseline only)
Number of subjects: 20
Study: 2511584

Group type: EXPERIMENTAL
Intervention: Computerized physician prompts for mammography referral, reminder postcards for scheduled appointments, telephone calls to encourage rescheduling of missed appointments.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elimination of out-of-pocket mammography expenses at three of the five sites.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated system of interventions (computer prompts, reduced expenses, appointment reminders).
Number of subjects: 0
Study: 1064903

Group type: EXPERIMENTAL
Intervention: Liquid antacid co-administered with ferrous salts (carbonate, fumarate, sulphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous carbonate with liquid antacid
Number of subjects: 0
Study: 31486766

Group type: EXPERIMENTAL
Intervention: Bacterial transposases
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Shorter bacterial transposases
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Longer bacterial transposases
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Archaeal transposases
Number of subjects: 112
Study: 29049382

Group type: EXPERIMENTAL
Intervention: Phone-based unannounced pill counts in START (Lesotho)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone-based unannounced pill counts in ENRICH (Ethiopia)
Number of subjects: 0
Study: 26614138

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2mg/kg + Propofol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3mg/kg + Propofol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Propofol alone (Control Group)
Number of subjects: 105
Study: 24063098

Group type: EXPERIMENTAL
Intervention: Alfaxalone 5 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfaxalone 10 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfaxalone 15 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfaxalone 100 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 22047561

Group type: EXPERIMENTAL
Intervention: Commercial disease-management programs using nurse-based call centers
Number of subjects: 242417

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 242417
Study: 19095850

Group type: EXPERIMENTAL
Intervention: Resistive heating under-patient blanket
Number of subjects: 56

Group type: COMPARATOR
Intervention: Forced-air warming system
Number of subjects: 56
Study: 17313906

Group type: EXPERIMENTAL
Intervention: Leisure centre-based exercise programme
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Instructor-led walking programme
Number of subjects: 943

Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 943
Study: 15160265

Group type: EXPERIMENTAL
Intervention: Fluoxetine at 20 mg/day for 12 weeks
Number of subjects: 10
Study: 11606923

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole cream
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1.0% metronidazole cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 72
Study: 9602580

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane with nitrous oxide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Halothane with nitrous oxide
Number of subjects: 80
Study: 7977476

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: On-line ST-segment monitoring with sestamibi injection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Predialysis imaging
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ST segment monitoring
Number of subjects: 18
Study: 2485616

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: pernazine
Number of subjects: 26
Study: 238548

Group type: EXPERIMENTAL
Intervention: Lorazepam 3 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lorazepam 5 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pentobarbitone 50 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30079756

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 322
Study: 29369450

Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined cohorts (baseline pain and PPT levels)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Baseline PPTs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Number of painful sites
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 200
Study: 27064060

Group type: EXPERIMENTAL
Intervention: R.A.P.I.D. system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enhanced Meditech (EM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enhanced Orchard (EO)
Number of subjects: 100
Study: 24484547

Group type: EXPERIMENTAL
Intervention: Lo‐AscA (50 mg/kg/24 h, n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hi‐AscA (200 mg/kg/24 h, n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (5% dextrose/water, n = 8)
Number of subjects: 24
Study: 22205317

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN) providing 130-150% of resting energy expenditure (REE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Titrated parenteral nutrition (PN) matched to measured REE
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both standard and titrated PN regimens
Number of subjects: 26
Study: 20807343

Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate 40 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study: 17200359

Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by FEC chemotherapy with concurrent trastuzumab for 24 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chemotherapy and trastuzumab
Number of subjects: 42
Study: 15660042

Group type: EXPERIMENTAL
Intervention: Rate-control treatment strategy
Number of subjects: 716

Group type: COMPARATOR
Intervention: Rhythm-control treatment strategy
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 716
Study: 12407485

Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg QD
Number of subjects: 89

Group type: COMPARATOR
Intervention: Lamivudine 150 mg BID
Number of subjects: 89
Study: 10207493

Group type: EXPERIMENTAL
Intervention: 40 mg of hyoscyamine butylbromide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no hyoscyamine butylbromide)
Number of subjects: 50
Study: 8527351

Group type: EXPERIMENTAL
Intervention: diltiazem CD 180 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: diltiazem SR 90 mg bid
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: diltiazem CD
Number of subjects: 111

Group type: COMPARATOR
Intervention: diltiazem SR
Number of subjects: 111
Study: 2695861

Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 100
Study: 1137285

Group type: EXPERIMENTAL
Intervention: Medical management for the initial 4 days in major hyphemas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0
Study: 31521666

Group type: EXPERIMENTAL
Intervention: 12-month intervention including training of patients and their primary care physicians in evidence-based post-sepsis care, case management by trained nurses, and clinical decision support for PCPs.
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care provided by primary care physicians (PCPs).
Number of subjects: 291
Study: 30698247

Group type: EXPERIMENTAL
Intervention: Diabetes Knowledge Scale (DKN‐A)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diabetes Attitudes Questionnaire (ATT‐19)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Living alone (protective factor)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Low education (risk factor)
Number of subjects: 202
Study: 28464014

Group type: EXPERIMENTAL
Intervention: Perineural 200 mg MgSO4 added to 0.25% ropivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.25% ropivacaine alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.375% ropivacaine alone
Number of subjects: 70
Study: 24595550

Group type: EXPERIMENTAL
Intervention: TU-100 (15 g/day, three times a day)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: TU-100
Number of subjects: 231
Study: 23780504

Group type: EXPERIMENTAL
Intervention: Test formulation of lansoprazole 30 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Reference formulation of lansoprazole 30 mg
Number of subjects: 156
Study: 20945151

Group type: EXPERIMENTAL
Intervention: Swim-trained girls during cycle exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untrained girls during cycle exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Swim-trained girls during upper body exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untrained girls during upper body exercise
Number of subjects: 16
Study: 18056225

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 16439444

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg (IFX/IFX)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (PBO/IFX)
Number of subjects: 104
Study: 12542586

Group type: EXPERIMENTAL
Intervention: Take‐home Diabetes Record (THDR)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no THDR)
Number of subjects: 127
Study: 10968529

Group type: EXPERIMENTAL
Intervention: Physiotherapy immediately following cast removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: No active therapy following cast removal
Number of subjects: 0
Study: 9578428

Group type: COMPARATOR
Intervention: Vaccination with ganglioside GM2 vaccine (GM2-KLH/QS-21)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Adjuvant therapy with high or low intermediate doses of IFN-alpha2b (10 MU subcutaneously every day, 5 days per week for 4 weeks, followed by either 10 MU subcutaneously, three times weekly for 1 year, or 5 MU subcutaneously, three times weekly for 2 years)
Number of subjects: 2000
Study: 8473717

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 weeks
Number of subjects: 23
Study: 3084616

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 2, 3, or 4.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 2.5 and 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cimetidine 300 mg iv
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sulpiride 10 mg im
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 32
Study: 31842048

Group type: EXPERIMENTAL
Intervention: RANDOM (randomized testing order)
Number of subjects: 50
Study: 30043066

Group type: EXPERIMENTAL
Intervention: Early in-bed leg cycling plus electrical stimulation of the quadriceps muscles added to standardized early rehabilitation (n=159)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Standardized early rehabilitation alone (usual care) (n=155)
Number of subjects: 314
Study: 27496662

Group type: EXPERIMENTAL
Intervention: Double Endobutton device (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Triple Endobutton device (group B)
Number of subjects: 80
Study: 25715902

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency treatment (UG-PRF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 100
Study: 23314413

Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 302

Group type: COMPARATOR
Intervention: Plastibell
Number of subjects: 302
Study: 22945782

Group type: EXPERIMENTAL
Intervention: Salacia chinensis 1000 mg twice-daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salacia chinensis
Number of subjects: 30
Study: 17917819

Group type: EXPERIMENTAL
Intervention: Physical Training (PT, n=71)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Physical Training plus Cognitive-Behavioural Training (PT+CBT, n=76)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 147
Study: 18650577

Group type: EXPERIMENTAL
Intervention: Simplified (single puncture) ilioinguinal and iliohypogastric nerve block with 0.1 ml/kg of 0.25% bupivacaine (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal block with 1 ml/kg of 0.25% bupivacaine (Group II)
Number of subjects: 60
Study: 12547466

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 10631196

Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients with no other source of fever
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients with pulmonary hemorrhage or infarction
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Acute pulmonary embolism (PE) patients without pulmonary hemorrhage or infarction
Number of subjects: 311
Study: 8765628

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a dose of 20 to 40 ppm, advanced to 80 ppm if PaO2 remained less than 100 mm Hg (13.3 kPa)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (conventional treatment without NO)
Number of subjects: 17
Study: 1608408

Group type: EXPERIMENTAL
Intervention: Educational program in geriatric psychopharmacology (experimental nursing homes)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Control nursing homes
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 823
Study: 2865422

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30285507

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (GON and SON blockade)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 87
Study: 30049885

Group type: EXPERIMENTAL
Intervention: CapOX plus bevacizumab (CapOX/BEV arm: bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 2,000 mg/m2 on days 1‐14, every 3 weeks)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CapIRI plus bevacizumab (CapIRI/BEV arm: bevacizumab 7.5 mg/kg and irinotecan 200 mg/m2 on day 1 and capecitabine 1,600 mg/m2 on days 1‐14, every 3 weeks)
Number of subjects: 107
Study: 27623721

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg tramadol (Group T0.5)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tramadol (Group T0.25)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Normal saline 0.05 ml/kg (Group TNS)
Number of subjects: 144
Study: 25141016

Group type: EXPERIMENTAL
Intervention: Papacárie®
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carisolv™
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manual (excavators)
Number of subjects: 46
Study: 23068783

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Boluses of analgesia (control)
Number of subjects: 0
Study: 20945260

Group type: EXPERIMENTAL
Intervention: PolyHeme®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood
Number of subjects: 0
Study: 18852400

Group type: EXPERIMENTAL
Intervention: Pay-for-performance program offering $5000 for 50 quitline referrals
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pay-for-performance program
Number of subjects: 49
Study: 15670982

Group type: EXPERIMENTAL
Intervention: 10 g/day sc-FOS for 5 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 11
Study: 11865814

Group type: EXPERIMENTAL
Intervention: TMTX 110 mg/m2 followed 24 h later by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue, given weekly for 6 weeks every 8 weeks.
Number of subjects: 365

Group type: COMPARATOR
Intervention: 5-FU 600 mg/m2 with LV 200 mg/m2, given weekly for 6 weeks every 8 weeks.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Both treatment arms (TMTX/5-FU/LV and 5-FU/LV)
Number of subjects: 365